HUMULIN R KWIKPEN

Clinical safety rating: caution

Comprehensive clinical and safety monograph for HUMULIN R KWIKPEN (HUMULIN R KWIKPEN).

How it works

Insulin lispro lowers blood glucose by binding to insulin receptors, increasing glucose uptake in skeletal muscle and adipose tissue, and inhibiting hepatic glucose production.

What the body does with it

Metabolism	Metabolized by insulin-degrading enzyme; no significant hepatic or renal clearance.
Excretion	Renal: 60-80% (metabolized to inactive peptides); hepatic metabolism via insulin-degrading enzyme; remainder reabsorbed in proximal tubule.
Half-life	5-10 minutes (intravenous); subcutaneous: 1.5-2 hours (depot absorption-limited).
Protein binding	<5% (primarily albumin, but minimal due to rapid clearance; also binds to insulin receptors).
Volume of Distribution	0.2-0.4 L/kg (confined largely to extracellular fluid; does not readily cross blood-brain barrier).
Bioavailability	Subcutaneous: 55-75% (variable due to injection site, depth, and local degradation).
Onset of Action	Subcutaneous: 30-60 minutes; intravenous: 10-30 minutes.
Duration of Action	Subcutaneous: 6-8 hours (regular insulin); intravenous: 30-90 minutes (dose-dependent).

Classification & Brands

Dosing & administration

Subcutaneous injection, individualize based on metabolic needs and blood glucose monitoring. Typical starting total daily insulin dose in type 1 diabetes: 0.5-1 unit/kg/day, with 50-60% as basal and 40-50% as prandial. In type 2 diabetes, initial total daily dose: 0.2-0.4 units/kg/day, with adjustments. Administer 30 minutes before meals.

Dosage form	SOLUTION
Renal impairment	Renal impairment may decrease insulin clearance, increasing risk of hypoglycemia. For eGFR <30 mL/min: reduce total daily dose by 20-50% based on glucose monitoring. Frequent dose titration recommended. Insulin requirements often decrease in advanced renal disease.
Liver impairment	Severe hepatic impairment (Child-Pugh class C) may impair gluconeogenesis, increasing hypoglycemia risk. Consider starting dose at 50% of standard and titrate slowly. For Child-Pugh class A or B, monitor closely; no specific dose reduction initially.
Pediatric use	Subcutaneous, individualize. For type 1 diabetes: 0.5-1 unit/kg/day total, with basal and bolus components. Adjust based on age, weight, and glycemic goals. For type 2 diabetes: start at 0.2-0.4 units/kg/day. Administer 30 minutes before meals.
Geriatric use	Start with lower doses (e.g., 0.2-0.4 units/kg/day total), titrate slowly to avoid hypoglycemia. Target less stringent glycemic goals (e.g., A1C <8.0%) based on comorbidities and life expectancy. Monitor renal function and adjust accordingly.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for HUMULIN R KWIKPEN (HUMULIN R KWIKPEN).

Breastfeeding	Insulin is excreted into breast milk in negligible amounts; no known adverse effects on nursing infant. M/P ratio not established. Use compatible with breastfeeding.
Teratogenic Risk	Insulin does not cross the placenta in significant amounts. No increased risk of major malformations with maternal use. Poor glycemic control increases congenital anomaly risk. Close monitoring recommended to maintain euglycemia.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

Changes in insulin strength, manufacturer, type, or method of administration should be made under close medical supervision to prevent adverse events such as hypoglycemia or hyperglycemia.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Hypersensitivity to insulin lispro or any excipients","During episodes of hypoglycemia"]

Clinical Precautions

Precautions

["Hypoglycemia is the most common adverse effect; monitor blood glucose.","Never share a KwikPen between patients, even if the needle is changed.","Changes in insulin regimen may require dose adjustment.","May cause hypokalemia; monitor potassium levels in patients at risk."]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

HUMULIN R KWIKPEN

Clinical safety rating: caution

Comprehensive clinical and safety monograph for HUMULIN R KWIKPEN (HUMULIN R KWIKPEN).

How it works

Insulin lispro lowers blood glucose by binding to insulin receptors, increasing glucose uptake in skeletal muscle and adipose tissue, and inhibiting hepatic glucose production.

What the body does with it

Metabolism	Metabolized by insulin-degrading enzyme; no significant hepatic or renal clearance.
Excretion	Renal: 60-80% (metabolized to inactive peptides); hepatic metabolism via insulin-degrading enzyme; remainder reabsorbed in proximal tubule.
Half-life	5-10 minutes (intravenous); subcutaneous: 1.5-2 hours (depot absorption-limited).
Protein binding	<5% (primarily albumin, but minimal due to rapid clearance; also binds to insulin receptors).
Volume of Distribution	0.2-0.4 L/kg (confined largely to extracellular fluid; does not readily cross blood-brain barrier).
Bioavailability	Subcutaneous: 55-75% (variable due to injection site, depth, and local degradation).
Onset of Action	Subcutaneous: 30-60 minutes; intravenous: 10-30 minutes.
Duration of Action	Subcutaneous: 6-8 hours (regular insulin); intravenous: 30-90 minutes (dose-dependent).

Classification & Brands

Dosing & administration

Dosage form	SOLUTION
Renal impairment	Renal impairment may decrease insulin clearance, increasing risk of hypoglycemia. For eGFR <30 mL/min: reduce total daily dose by 20-50% based on glucose monitoring. Frequent dose titration recommended. Insulin requirements often decrease in advanced renal disease.
Liver impairment	Severe hepatic impairment (Child-Pugh class C) may impair gluconeogenesis, increasing hypoglycemia risk. Consider starting dose at 50% of standard and titrate slowly. For Child-Pugh class A or B, monitor closely; no specific dose reduction initially.
Pediatric use	Subcutaneous, individualize. For type 1 diabetes: 0.5-1 unit/kg/day total, with basal and bolus components. Adjust based on age, weight, and glycemic goals. For type 2 diabetes: start at 0.2-0.4 units/kg/day. Administer 30 minutes before meals.
Geriatric use	Start with lower doses (e.g., 0.2-0.4 units/kg/day total), titrate slowly to avoid hypoglycemia. Target less stringent glycemic goals (e.g., A1C <8.0%) based on comorbidities and life expectancy. Monitor renal function and adjust accordingly.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for HUMULIN R KWIKPEN (HUMULIN R KWIKPEN).

Breastfeeding	Insulin is excreted into breast milk in negligible amounts; no known adverse effects on nursing infant. M/P ratio not established. Use compatible with breastfeeding.
Teratogenic Risk	Insulin does not cross the placenta in significant amounts. No increased risk of major malformations with maternal use. Poor glycemic control increases congenital anomaly risk. Close monitoring recommended to maintain euglycemia.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

Changes in insulin strength, manufacturer, type, or method of administration should be made under close medical supervision to prevent adverse events such as hypoglycemia or hyperglycemia.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Hypersensitivity to insulin lispro or any excipients","During episodes of hypoglycemia"]